A peptide fragment of ApoE and an α7 nAChR antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

COG133 (trifluoroacetate salt)

Item No. 33587

Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-acetyl-L-leucyl-L-arginyl-L-valyl-L-arginyl-L-leucyl-L-alanyl-L-seryl-L-histidyl-L-leucyl-L-arginyl-L-lysyl-L-leucyl-L-arginyl-L-lysyl-L-arginyl-L-leucyl-L-leucinamide, trifuoroacetate salt
CAS Number
514200-66-9
Synonyms
  • Ac-LRVRLASHLRKLRKRLL-NH2
  • ApoE (133-149)
Molecular Formula
C97H181N37O19 • XCF3COOH
Formula Weight
2169.7
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: 1 mg/mlPBS (pH 7.2): 1 mg/ml
SMILES
CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CO)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@@H](NC(C)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)CC1=CN=CN1)=O)=O)=O)=O)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C97H181N37O19.C2HF3O2/c1-50(2)40-67(76(100)137)127-89(150)72(45-55(11)12)130-82(143)64(30-23-37-114-95(105)106)122-78(139)60(26-17-19-33-98)120-79(140)62(28-21-35-112-93(101)102)123-87(148)70(43-53(7)8)129-81(142)61(27-18-20-34-99)121-80(141)63(29-22-36-113-94(103)104)124-88(149)71(44-54(9)10)131-90(151)73(46-59-47-111-49-117-59)132-91(152)74(48-135)133-77(138)57(15)118-85(146)69(42-52(5)6)128-83(144)65(31-24-38-115-96(107)108)126-92(153)75(56(13)14)134-84(145)66(32-25-39-116-97(109)110)125-86(147)68(41-51(3)4)119-58(16)136;3-2(4,5)1(6)7/h47,49-57,60-75,135H,17-46,48,98-99H2,1-16H3,(H2,100,137)(H,111,117)(H,118,146)(H,119,136)(H,120,140)(H,121,141)(H,122,139)(H,123,148)(H,124,149)(H,125,147)(H,126,153)(H,127,150)(H,128,144)(H,129,142)(H,130,143)(H,131,151)(H,132,152)(H,133,138)(H,134,145)(H4,101,102,112)(H4,103,104,113)(H4,105,106,114)(H4,107,108,115)(H4,109,110,116);(H,6,7)/t57-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-;/m0./s1
InChi Key
YRYTWYOGXATSSP-BGJGLIJFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $119

    Add

    5 mg

    $451

    Add

    10 mg

    $740

    Add

    25 mg

    $1,055

    Add
    Product Description

    COG133 is a peptide fragment of ApoE that corresponds to residues 133-149 of the ApoE LDL receptor-binding domain and an antagonist of α7 nicotinic acetylcholine receptors (nAChRs; IC50 = 720 nM).1,2 It suppresses TNF-α and nitric oxide (NO) release in BV-2 microglia when used at concentrations ranging from 10 to 50 µM.1 In vivo, COG133 reduces LPS-induced increases in brain levels of TNF-α and IL-6 in mice.3 It decreases hippocampal neuronal degeneration and the latency to find the platform in the Morris water maze in a mouse model of closed head injury induced by surgical midline impact when administered at doses of 203 and 406 µg/kg.4 COG133 (1 mg/kg) also delays disease onset and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis (EAE).5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Laskowitz, D.T., Thekdi, A.D., Thekdi, S.D., et al. Downregulation of microglial activation by apolipoprotein E and ApoE-mimetic peptides. Exp. Neurol. 167(1), 74-85 (2001).

    2. Klein, R.C., and Yakel, J.L. Inhibition of nicotinic acetylcholine receptors by apolipoprotein E-derived peptides in rat hippocampal slices. Neuroscience 127(3), 563-567 (2004).

    3. Lynch, J.R., Tang, W., Wang, H., et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. The Journal of Biological Chemisty 278(49), 48529-48533 (2003).

    4. Lynch, J.R., Wang, H., Mace, B., et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp. Neurol. 192(1), 109-116 (2005).

    5. Li, F.-Q., Sempowski, G.D., McKenna, S.E., et al. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. Pharmacol. Exp. Ther. 318(3), 956-965 (2006).